Literature DB >> 26430549

Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans.

Luisa Diomede1, Paola Rognoni2, Francesca Lavatelli2, Margherita Romeo1, Andrea di Fonzo2, Claudia Foray3, Fabio Fiordaliso3, Giovanni Palladini4, Veronica Valentini2, Vittorio Perfetti5, Mario Salmona1, Giampaolo Merlini4.   

Abstract

Abnormalities in protein folding are involved in many localized and systemic diseases, all of which are characterized by insoluble amyloid formation and deposition. In immunoglobulin light chain (LC) amyloidosis, the most frequent systemic form of amyloidosis, the amyloid involvement of the heart dictates the prognosis and the elucidation of the mechanism of heart targeting and toxicity is essential for designing and testing new effective treatments. To this end, the availability of an appropriate animal model is crucial. We recently described the use of C. elegans as an innovative experimental system to investigate in vivo the pathogenic effects of monoclonal LC. This idea stems from the knowledge that the worm's pharynx is an "ancestral heart" with the additional ability to recognize stressor compounds. The feeding of worms with LC purified from patients suffering from cardiomyopathy, selectively and permanently impaired the pharyngeal function. This irreversible damage resulted in time, in a significant reduction in the lifespan of worms. We also reported that the ability of LC to generate reactive oxygen species was associated with their toxic effects and was counteracted by anti-oxidant compounds. This new nematode-based assay represents a promising model for elucidating the heart-specific toxicity of LC and for a rapid screening of new therapeutic strategies.

Entities:  

Keywords:  C. elegans; amyloidosis; cardiotoxicity; immunoglobulin light chains; pharynx

Year:  2014        PMID: 26430549      PMCID: PMC4588172          DOI: 10.4161/21624046.2014.965590

Source DB:  PubMed          Journal:  Worm        ISSN: 2162-4046


  32 in total

1.  β-Amyloid peptide increases levels of iron content and oxidative stress in human cell and Caenorhabditis elegans models of Alzheimer disease.

Authors:  Li Wan; Guangjun Nie; Jie Zhang; Yunfeng Luo; Peng Zhang; Zhiyong Zhang; Baolu Zhao
Journal:  Free Radic Biol Med       Date:  2010-10-26       Impact factor: 7.376

Review 2.  Invertebrate models of Alzheimer's disease.

Authors:  C D Link
Journal:  Genes Brain Behav       Date:  2005-04       Impact factor: 3.449

Review 3.  A new face for old antibiotics: tetracyclines in treatment of amyloidoses.

Authors:  Tatiana Stoilova; Laura Colombo; Gianluigi Forloni; Fabrizio Tagliavini; Mario Salmona
Journal:  J Med Chem       Date:  2013-05-08       Impact factor: 7.446

Review 4.  Amyloidosis: pathogenesis and new therapeutic options.

Authors:  Giampaolo Merlini; David C Seldin; Morie A Gertz
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

5.  Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish.

Authors:  Shikha Mishra; Jian Guan; Eva Plovie; David C Seldin; Lawreen H Connors; Giampaolo Merlini; Rodney H Falk; Calum A MacRae; Ronglih Liao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-26       Impact factor: 4.733

6.  Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts.

Authors:  R Liao; M Jain; P Teller; L H Connors; S Ngoy; M Skinner; R H Falk; C S Apstein
Journal:  Circulation       Date:  2001-10-02       Impact factor: 29.690

Review 7.  Caenorhabditis elegans as a model system to study intercompartmental proteostasis: Interrelation of mitochondrial function, longevity, and neurodegenerative diseases.

Authors:  Janine Kirstein-Miles; Richard I Morimoto
Journal:  Dev Dyn       Date:  2010-05       Impact factor: 3.780

8.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.

Authors:  Giovanni Palladini; Angela Dispenzieri; Morie A Gertz; Shaji Kumar; Ashutosh Wechalekar; Philip N Hawkins; Stefan Schönland; Ute Hegenbart; Raymond Comenzo; Efstathios Kastritis; Meletios A Dimopoulos; Arnaud Jaccard; Catherine Klersy; Giampaolo Merlini
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

9.  Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity.

Authors:  Jian Guan; Shikha Mishra; Jianru Shi; Eva Plovie; Yiling Qiu; Xin Cao; Davide Gianni; Bingbing Jiang; Federica Del Monte; Lawreen H Connors; David C Seldin; Francesca Lavatelli; Paola Rognoni; Giovanni Palladini; Giampaolo Merlini; Rodney H Falk; Marc J Semigran; G William Dec; Calum A Macrae; Ronglih Liao
Journal:  Basic Res Cardiol       Date:  2013-08-28       Impact factor: 17.165

10.  A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis.

Authors:  Luisa Diomede; Paola Rognoni; Francesca Lavatelli; Margherita Romeo; Elena del Favero; Laura Cantù; Elena Ghibaudi; Andrea di Fonzo; Alessandro Corbelli; Fabio Fiordaliso; Giovanni Palladini; Veronica Valentini; Vittorio Perfetti; Mario Salmona; Giampaolo Merlini
Journal:  Blood       Date:  2014-03-24       Impact factor: 22.113

View more
  2 in total

Review 1.  Immunoglobulin light chain amyloid aggregation.

Authors:  Luis M Blancas-Mejia; Pinaki Misra; Christopher J Dick; Shawna A Cooper; Keely R Redhage; Michael R Bergman; Torri L Jordan; Khansaa Maar; Marina Ramirez-Alvarado
Journal:  Chem Commun (Camb)       Date:  2018-09-20       Impact factor: 6.222

2.  Rebaudioside A Enhances Resistance to Oxidative Stress and Extends Lifespan and Healthspan in Caenorhabditis elegans.

Authors:  Pan Li; Zehua Wang; Sin Man Lam; Guanghou Shui
Journal:  Antioxidants (Basel)       Date:  2021-02-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.